By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN
The full-day panel schedule at RESI Boston on June 16 will spotlight the top investment themes shaping the life science ecosystem. From family offices and health systems to pharma and AI-focused funds, the RESI stage will feature active investors across the spectrum sharing how they evaluate opportunities and what’s driving their deal flow.
Panels will cover key topics such as sector-specific outlooks, alternative funding sources, emerging technologies, and cross-border strategy. These sessions are designed for entrepreneurs to better understand investor priorities, refine their pitch, and build lasting relationships in the industry.
RESI Boston takes place in person at the Westin Copley Place on June 16, with virtual partnering continuing June 17–18 and June 23. Whether you’re attending in person or virtually, don’t miss this opportunity to hear directly from investors who are actively shaping the future of healthcare innovation.
Join the panelists below at RESI Boston June:
![]() John Abeles General Partner Northlea Partners |
![]() Salma Al-Zu’bi Investment Principal Hikma Ventures |
![]() Marc Appel Managing Partner Pacific Bridge NY |
![]() Caleb Bell Advisor Beyond Next Ventures |
![]() Ethan Berg Managing Partner G4 Investments, LLC |
![]() John Boyce Managing Director & Co-Founder 28 Capital |
![]() Dirk Büscher Sr Director Grifols Innovation & New Technologies Grifols |
![]() Danny Carbonero Investor PsyMed Ventures |
![]() Nicolas Cindric Partner Yahara Ventures |
![]() Leo Cui Partner FoundersX |
![]() Bettina Ernst Director BERNINA BioInvest |
![]() Marc Estigarribia Managing Director MSQ Ventures |
![]() Eileen Flowers, PhD Director, Technology Development & Licensing Memorial Sloan Kettering Cancer Center |
![]() Ser-Chen Fu Partner Pacific 8 Ventures |
![]() Ayah Hamdan Director & Ventures, Health Plug and Play Ventures |
![]() Zizi Imatorbhebhe CEO & Executive Partner Bios Health Group |
![]() Cheryl Kuai Managing Director Sixty Degree Capital |
![]() Michael Langer Founder & Managing Partner T.Rx Capital |
![]() John Leader Partner Green Park & Golf Ventures |
![]() Chloé Lepretre Head of Global R&D Search & Evaluation Servier |
![]() Andrew Merken Shareholder Polsinelli PC |
![]() Fiona Miller Managing Partner quadraScope Venture Fund |
![]() Ravi Mistry Venture Partner / Officer & Founding Team Member 3i Partners |
![]() Ralph Morales III Venture Partner / Executive-in-Residence Aquillius Ventures |
![]() Daniel O’Mahony Partner Seroba Life Sciences |
![]() John Parker Founder & Managing Director Springhood Ventures |
![]() John Pennett Angel Investor Mid Atlantic Bio Angels |
![]() Prashant Shah Partner O2h Ventures |
![]() Jeremy Sohn Managing Partner P74 Ventures |
![]() Nicolas Stalder Sr. Investment Manager Debiopharm Innovation Fund |
![]() Adam Steinert CTO Yahara Ventures |
![]() Jeff Stinson Director HealthTech Arkansas |
![]() Alex Strasser Sr. Associate Apollo Health Ventures |
![]() Bob Sweeney Principal & Co-Founder Global Health Impact Fund |
![]() Thomas Thornton Vice President, Innovation, Jefferson Ventures Jefferson Health |
![]() John Tremblay Investor Launchpad Venture Group |
![]() Mark Vreeke Co-Founder Chemical Angel Network |
![]() Sally Wang Liang Managing Partner Xpanse Venture |
![]() Don Zinn US Vice President US Business Crossject |














































Leave a comment